While RxSight has made strides in improving its gross margin and increasing LAL revenue, the company faced significant challenges with overall revenue decline and a substantial decrease in LDD sales. The global expansion efforts and positive market reception of the Light Adjustable Lens are promising, but the increased net loss and revenue challenges present concerns.

Company Guidance

During the call, RxSight provided updated guidance for the fiscal year 2025, narrowing its revenue expectations to a range of $125 million to $130 million, up from the previous range of $120 million to $130 million. The company anticipates a gross margin between 76% to 77%, an increase from the prior guidance of 72% to 74%. For the fourth quarter, RxSight expects revenues between $23 million and $28 million, with an implied year-over-year decline of 11% to 7%. Operating expenses are projected to be between $145 million and $155 million, including non-cash stock-based compensation expenses of $30 million to $32 million. The company continues to focus on expanding the Light Adjustable Lens (LAL) adoption, with LAL procedures seen as a leading metric for growth.

Gross Margin Improvement

Gross margin in Q3 2025 was 79.9%, an 844 basis point increase compared to Q3 2024 and a 496 basis point increase compared to Q2 2025. This improvement was driven by a higher LAL mix and lower unit costs.

LAL Revenue Growth

Revenue from Light Adjustable Lenses (LAL) increased by 6% compared to Q3 2024, representing 85% of total revenue, up from 69% in Q3 2024 and 80% in Q2 2025.

Strategic Global Expansion

Successful progress in rolling out in Asia and Europe, with regulatory infrastructure and commercial initiatives supporting multiyear expansion across priority global markets.

Positive Market Reception

Strong global clinical and market enthusiasm for the Light Adjustable Lens, with increasing interest at international meetings such as the ESCRS and AAO.

RxSight (RXST) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RXST Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 10, 2026	2025 (Q4)	-0.34 / -	-0.15	―	―	―
Nov 05, 2025	2025 (Q3)	-0.38 / -0.24	-0.16	-50.00% (-0.08)	―
Aug 07, 2025	2025 (Q2)	-0.25 / -0.29	-0.16	-81.25% (-0.13)	―
May 07, 2025	2025 (Q1)	-0.22 / -0.20	-0.25	20.00% (+0.05)	―
Feb 25, 2025	2024 (Q4)	-0.17 / -0.15	-0.26	42.31% (+0.11)	―
Nov 07, 2024	2024 (Q3)	-0.25 / -0.16	-0.35	54.29% (+0.19)	―
Aug 05, 2024	2024 (Q2)	-0.22 / -0.16	-0.4	60.00% (+0.24)	―
May 06, 2024	2024 (Q1)	-0.29 / -0.25	-0.42	40.48% (+0.17)	―
Feb 28, 2024	2023 (Q4)	-0.37 / -0.26	-0.56	53.57% (+0.30)	―
Nov 09, 2023	2023 (Q3)	-0.43 / -0.35	-0.61	42.62% (+0.26)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

RXST Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 05, 2025	$8.34	$8.61	+3.24%
Aug 07, 2025	$7.79	$7.19	-7.70%
May 07, 2025	$14.90	$13.23	-11.21%
Feb 25, 2025	$29.21	$28.97	-0.82%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does RxSight (RXST) report earnings?

RxSight (RXST) is schdueled to report earning on Mar 10, 2026, After Close (Confirmed).

What is RxSight (RXST) earnings time?

RxSight (RXST) earnings time is at Mar 10, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is RXST EPS forecast?

RXST EPS forecast for the fiscal quarter 2025 (Q4) is -0.34.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing